<div id="readability-page-1"><p>China Universal Asset Management Co. Ltd. acquired a new stake in  Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor  acquired 11,619 shares of the company's stock, valued at approximately $1,567,000.</p><p>A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Jefferies Financial Group Inc. bought a new position in  Abivax during the third quarter worth about $38,827,000.  Federated Hermes Inc. bought a new stake in shares of  Abivax in the 3rd quarter valued at approximately $8,448,000.  Persistent Asset Partners Ltd bought a new stake in shares of  Abivax in the 3rd quarter valued at approximately $815,000.  Atika Capital Management LLC acquired a new position in shares of  Abivax in the 3rd quarter worth approximately $5,858,000.  Finally, Tudor Investment Corp ET AL acquired a new position in shares of  Abivax in the 3rd quarter worth approximately $2,792,000. 47.91% of the stock is owned by institutional investors. </p><h2>Abivax Price Performance</h2><p>NASDAQ ABVX opened at $114.56 on Friday. The stock's 50 day simple moving average is $118.27 and its 200 day simple moving average is $115.69. Abivax SA Sponsored ADR has a one year low of $5.59 and a one year high of $148.83. The firm has a market cap of $9.08 billion, a PE ratio of -21.33 and a beta of 1.68. </p><p>Abivax (NASDAQ:ABVX - Get Free Report) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($1.20) earnings per share (EPS) for the quarter. The business had revenue of $0.52 million during the quarter.  As a group, equities analysts expect that  Abivax SA Sponsored ADR will post -3.84 earnings per share for the current year. </p><h2>Analyst Upgrades and Downgrades</h2><p>ABVX has been the topic of several recent analyst reports. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Abivax in a research note on Monday. BTIG Research  reissued a &#34;buy&#34; rating and set a $150.00 price objective on shares of Abivax in a report on Wednesday, February 25th. Citigroup  restated a &#34;market outperform&#34; rating on shares of Abivax in a research note on Thursday, January 8th. Barclays upped their target price on shares of Abivax from $142.00 to $148.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, March 24th. Finally, Wedbush initiated coverage on shares of Abivax in a research report on Tuesday, February 24th. They set an &#34;outperform&#34; rating and a $110.00 target price for the company. One equities research analyst  has rated the stock with a Strong Buy rating, thirteen have assigned  a Buy rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat, Abivax  has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $137.15.</p><p><b>View Our Latest Analysis on Abivax</b></p><h2>About Abivax</h2> (Free Report)<p>Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles. </p><p>Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.</p><h2>Read More</h2><ul><li>Five stocks we like better than Abivax</li></ul><p><strong>Want to see what other hedge funds are holding ABVX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Abivax Right Now?</h2><p>Before you consider Abivax, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.</p><p>While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABVX

LABU

<p>China Universal Asset Management Co. Ltd. has acquired 11,619 shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) valued at approximately $1.57 million, as reported in its recent 13F filing. Other institutional investors have also increased their stakes in Abivax. The stock has a market cap of $9.08 billion and a PE ratio of -21.33. Analysts have mixed ratings on Abivax, with a consensus rating of "Moderate Buy" and a price target of $137.15. Abivax focuses on developing therapies for chronic inflammatory diseases and viral infections.</p>

Market Beat

Abivax SA

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Jefferies Financial

Federated Hermes

Citigroup

Barclays

CITIGROUP INC 6.250 NON CUM SER II PFD WI

China Universal Asset Management Co. Ltd. Purchases Shares of 11,619 Abivax SA Sponsored ADR $ABVX